Goodwin advised HiberCell on the deal HiberCell, a biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, finalized its $60.75 Million Series A funding…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Ambrogio Visconti
…
This content is for Standard 1 Year members only. LoginJoin Now